Open-label observational study of the homeopathic medicine Passiflora Compose for anxiety and sleep disorders

Background: Anxiety and sleep disorders (SDS) are frequently treated with psychotropic drugs. Health authorities in France have been advised to improve access to alternative treatments such as homeopathic medicines. Our aim was to describe the socio-demographic characteristics and clinical progression of patients prescribed homeopathic medicine Passiflora Compose (PC) for anxiety and/or SDS.

Material and methods: This was an open-label, observational study. Randomly selected general practitioners (GPs) known to prescribe homeopathic medicines recruited consecutive patients (≥18-years) prescribed PC. The following data were recorded at inclusion by the GP: socio-demographic data and anxiety severity (Hamilton anxiety rating scale or HAM-A); and by the patients: level of anxiety (STAI Spielberger self-assessment questionnaire) and SDS (Jenkins sleep scale or JSS). Anxiety and SDS were reassessed after 4 weeks of treatment using the same scales.

Results: A total of 639 patients (mean age: 46.3 ± 17.5 years; 78.6% female) were recruited by 98 GPs. Anxiety was present in 85.4% (HAM-A) and 93.3% (Spielberger State) at inclusion (mean scores: 17.8 ± 8.91 and 54.59 ± 11.69, respectively) and SDS was present in 74.0% (mean score: 15.24 ± 5.28). A total of 401 (62.7%) patients received PC alone and 167 (26.1%) PC + psychotropics. After 4 weeks, mean anxiety scores decreased by more than 7, 12 and 6 points (HAM-A, Spielberger State and Trait respectively), and SDS score by more than 4 points (JSS).

Conclusion: Anxiety and/or SDS improved significantly in patients included on this study. PC could be an alternative to the use of psychotropic drugs for first intention treatment of anxiety and SDS. Further studies are needed to confirm those results.

Keywords

Passiflora Compose - Homeopathy - Psychotropic drugs - Anxiety - Sleep disorders - Observational study

• References

• 1 Ohayon M.M., Lemoine P. Daytime consequences of insomnia complaints in the French general population. Encephale 2004; 30: 222-227 [article in French].
• 2 Leger D., Poursain B. An international survey of insomnia: under-recognition and under-treatment of a polysymptomatic condition. Curr Med Res Opin 2005; 21: 1785-1792.
• 3 Giordanella J.P. Rapport sur le thème du sommeil. Ministère de la Santé et des Solidarités, Décembre 2006. 2006. Available at: www.ladocumentationfrancaise.fr/var/storage/rapports-publics/064000899/0000.pdf (last accessed 27/2/14).
• 4 Walsh J.K. Clinical and socioeconomic correlates of insomnia. J Clin Psychiatry 2004; 65 (08) 13-19.
• 5 Briot M. Office parlementaire d’évaluation des politiques de santé rapport sur le bon usage des psychotropes. 2006. [in French]. Available at: www.senat.fr/rap/r05-422/r05-422.html (last accessed 27/2/14).
• 6 Demarque D., Jouanny J., Poitevin B., Saint-Jean Y., Masson JL. Pharmacologie et Matière médicale homéopathique. 3e édition CEDH: 2003: 278-282.
• 7 Sarembaud A., Poitevin B. Médicaments à usage homéopathique Dictionnaire pratique. Masson: 1996. Paris; 71.
• 8 Cintract M. Remèdes homéopathiques des maux courants. 2003. Paris: Tec & DocEditions Médicales Internationales p. 221.
• 9 Boulet J., Loupias J.-P. Fiches de matière médicale. CEDH: 2008: 162-163.
• 10 Vannier L., Poirier J. Précis de matière médicale homéopathique. CEDH: 2005: 160-162 Manuscrit 1929-8e édition 1962 (15ème tirage – février 2005).
• 11 Bell I.R., Howerter A., Jackson N., Aickin M., Baldwin C.M., Bootzin R.R. Effects of homeopathic medicines on polysomnographic sleep of young adults with histories of coffee-related insomnia. Sleep Med 2011; 12 (05) 505-511.
• 12 Kolia-Adam N., Solomon E., Bond J., Deroukakis M. The efficacy of Coffea cruda on insomnia: a double blind trial. Simillimum 2008; XXI: 91-99.
• 13 Ruiz-Vega G., Perez-Ordaz L., Cortes-Galvan L., Juarez-G F.M. A kinetic approach to caffeine-Coffea cruda interaction. Homeopathy 2003; 92: 19-29.
• 14 Marzotto M., Conforti A., Magnani P., Zanolin M.E., Bellavite P. Effects of Ignatia amara in mouse behavioural models. Homeopathy 2012; 101: 57-67.
• 15 ADELF, ADEREST, AEEMA, EPITER. Recommendations for Professional Standards and Good Epidemiological Practices. ADELF: Saint Maurice; 2007.
• 16 Schweitzer Paulhan. Manuel pour l'inventaire d'anxiété trait-état (Forme Y). Laboratoire de Psychologie de la Santé, Université de Bordeaux II, 1990. 1990. Available at: www.spiralibre.com/tests/Anxiete.pdf (last accessed 27/2/14).
• 17 Vahtera J., Pentti J., Helenius H., Kivimāki M. Sleep disturbances as a predictor of long-term increase in sickness absence among employees after family death or illness. Sleep 2006; 29: 673-682.
• 18 Pilkington K., Kirkwood G., Rampes H., Fisher P., Richardson J. Homeopathy for anxiety and anxiety disorders: a systematic review of the research. Homeopathy 2006; 95: 151-162.
• 19 Davidson J.R., Crawford C., Ives J.A., Jonas W.B. Homeopathic treatments in psychiatry: a systematic review of randomized placebo-controlled studies. J Clin Psychiatry 2011; 72 (06) 795-805.
• 20 Schäfer T. Epidemiology of complementary alternative medicine for asthma and allergy in Europe and Germany. Ann Allergy Asthma Immunol 2004; 93 (02) suppl. 1 S5-S10.
• 21 Bücker B., Groenewold M., Schoefer Y., Schäfer T. The use of complementary alternative medicine (CAM) in 1 001 German adults: results of a population-based telephone survey. Gesundheitswesen 2008; 70: e29-e36.
• 22 Guethlin C., Walach H., Naumann J., Bartsch H.H., Rostock M. Characteristics of cancer patients using homeopathy compared with those in conventional care: a cross-sectional study. Ann Oncol 2010; 21: 1094-1099.